EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy

Xueyan Chen, Qi Gao iD, Mikhail Roshal, Sindhu Cherian

Cytometry Part B: Clinical Cytometry · 2023-05 · 104 (3) · 205-223

DOI: 10.1002/cyto.b.22113 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 22.01.2023. Verfasst von Xueyan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 133 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minimal/measurable residual disease (MRD) is the most important independent prognostic factor for patients with B‐lymphoblastic leukemia (B‐LL). MRD post therapy has been incorporated into risk stratification and clinical management, resulting in substantially improved outcomes in pediatric and adult patients. Currently, MRD in B‐ALL is most commonly assessed by multiparametric flow cytometry and molecular (polymerase chain reaction or high‐throughput sequencing based) methods. The detection of MRD by flow cytometry in B‐ALL often begins with B cell antigen‐based gating strategies. Over the past several years, targeted immunotherapy directed against B cell markers has been introduced in patients with relapsed or refractory B‐ALL and has demonstrated encouraging results. However, targeted therapies have significant impact on the immunophenotype of leukemic blasts, in particular, downregulation or loss of targeted antigens on blasts and normal B cell precursors, posing challenges for MRD detection using standard gating strategies. Novel flow cytometric approaches, using alternative strategies for population identification, sometimes including alternative gating reagents, have been developed and implemented to monitor MRD in the setting of post targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor B-Cell Lymphoblastic Leukemia-LymphomaBurkitt LymphomaAdultChildHumansFlow CytometryB-LymphocytesNeoplasm, ResidualImmunotherapy

Stichwörter der Autor:innen

B-lymphoblastic leukemia/lymphomaflow cytometryminimal/measurable residual diseasetargeted immunotherapy

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Qi Gao

Zitieren

APA

Chen, X., Gao, Q., Roshal, M., & Cherian, S. (2023). Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy. Cytometry Part B: Clinical Cytometry, 104(3), 205-223. https://doi.org/10.1002/cyto.b.22113

Vancouver

Chen X, Gao Q, Roshal M, Cherian S. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy. Cytometry Part B: Clinical Cytometry. 2023;104(3):205-223. doi:10.1002/cyto.b.22113

BibTeX
@article{Chen2023,
  author = {Chen, Xueyan and Gao, Qi and Roshal, Mikhail and Cherian, Sindhu},
  title = {Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2023},
  volume = {104},
  number = {3},
  pages = {205--223},
  doi = {10.1002/cyto.b.22113}
}
Kostenlos starten →